Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01773538|
Recruitment Status : Completed
First Posted : January 23, 2013
Last Update Posted : February 23, 2016
|Condition or disease||Intervention/treatment||Phase|
|Liver Cirrhosis Hepatic Encephalopathy||Drug: Lactulose and rifaximin Dietary Supplement: Branched Chain amino acids Other: Placebo||Not Applicable|
Objective: The aim of this project is to investigate whether continuous reaction time measurements (CRT) are suitable as a screening and monitoring tool for covert hepatic encephalopathy (c/mHE).
Sub-protocol 1: As a part of this PhD protocol 100 healthy individuals and 50 with chronic disease (not liver cirrhosis) will be tested using the CRT and PSE tests. This is to determine the normal range for the PSE test in the Danish population.
Sub-protocol 2: A total of 120 (aprox. 145 to adjust for drop outs) patients with liver cirrhosis from two Danish hospitals will be examined with both CRT and with the test that is the closest we get to a gold standard, namely portosystemic encephalopathy test (PSE). We wish to examine if the CRT test agrees with the PSE test, which may be to time consuming to perform in everyday clinical practice, and with quality of life scores (SF-36 and Sickness Impact Profile). The relationship between the CRT and PSE test and various blood tests and the Charlston co-morbidity score will also be examined.
Sub-protocol 3: Forty-four of the 120 included patients will, regardless of CRT test result, be randomized to treatment with lactulose, rifaximin and branched chain amino acids (BCAA) or placebo lactulose, rifaximin and BCAA. This is to evaluate whether the CRT method is able to detect a response to treatment, and see if changes in psychometric tests (PSE and CRT) are in accordance with quality of life scores and predicts subsequent development of overt hepatic encephalopathy.
Perspective: CRT method should, if it proves good enough, continue to be the Danish test of choice and hopefully be more widely used in our country. The validation of tests for the diagnosis of covert hepatic encephalopathy will give cirrhotic patients with covert hepatic encephalopathy and reduced quality of life the best opportunity to be diagnosed and offered appropriate treatment. If the CRT method is not able to identify a population that benefits from anti-encephalopathy treatment other screening and monitoring tests should be used.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||136 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||October 2015|
|Actual Study Completion Date :||November 2015|
Active Comparator: Anti cHE treatment arm
Of 150 included patients aprox. 44 regardless of CRT and PSE test outcome will be offered to enter randomisation and 3 months follow up. Half of 44 patients will receive both lactulose, rifaximin and branched chain aminoacids (Bramino) the other half placebo.
Drug: Lactulose and rifaximin
3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.Dietary Supplement: Branched Chain amino acids
30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
Placebo Comparator: Placebo arm
The goal of this intervention is to investigate whether the CRT method can detect an expected treatment response after initiation of the 3 named drugs know to ameliorate HE symptoms including psychometric test results.
Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
- Change in Continuous Reaction Time Method versus Portosystemic Encephalopathy Test [ Time Frame: baseline and 3 months ]The investigators are evaluating if the CRT and PSE test are in accordance at inclusion and after 3 months of treatment.
- Change in Continuous Reaction Time Method versus Quality of Life (QoL) [ Time Frame: baseline and 3 months ]The results from both CRT and PSE test will be compared to the out come of the SF-36 and the SIP (Sickness impact profile) QoL measurements.
- Correlation between CRT test and PSE test at inclusion [ Time Frame: at baseline ]The investigators wish to evaluate the correlation between the CRT and the PSE test at base line.
- Correlation between psychometric test results and quality of life af base line [ Time Frame: at base line ]The investigators wish to evaluate the correlation between the psychometric test results (CRT test result and PSE test result) and quality of life. The scientific question is which test correlates best to QoL.
- Danish normal values for the PSE test [ Time Frame: at base line ]100 normal Danish persons will be tested using the PSE test to establish the Danish norm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01773538
|Hospital of South West Jutland|
|Esbjerg, Denmark, 6700|
|Odense University Hospital|
|Odense, Denmark, 5000|
|Study Director:||Ove Schaffalitzky de Muckadell, Professor||Odense University Hospital|
|Study Chair:||Jeppe Gram, PhD, MD||Hospital of South West Jutland|
|Study Chair:||Hendrik Vilstrup, Professor||Aarhus University Hospital|